公司简介

Replimune develops the next generation of 'oncolytic immunotherapies' for the treatment of cancer.

主要成员

Robert、Coffin,、Philip、Sparke。

产品/服务

• 肿瘤基因组

Oncolytic Immunotherapy	Developing the next generation of oncolytic immunotherapy。
RP1 treats large injected & uninjected tumors	is based on a proprietary strain of herpes simplex virus engineered for tumor selectivity and enhanced systemic potency through the expression of a potent fusogenic glycoprotein。
RP2/3	RP2 and RP3 are versions of RP1 which additionally express an antibody-like molecule against CTLA-4 or the anti-CTLA-4 molecule together with optimized immune co-stimulatory pathway ligands. 。

融资信息

融资轮次	融资日期	投资方	融资额度
A轮	2015-09	Omega Funds、Atlas Venture、Forbion Capital Partners	$30M
B轮	2017-09	Foresite Capital、Leerink Partners、Cormorant Asset Management、Redmile Group	$55M

关联公司